BMS at #EULAR2020

Pursuing the advancement of precision medicines through biomarker science in immune-mediated diseases for patients with unmet needs

Intended for U.S. scientific audiences only.

At the European League Against Rheumatism (EULAR) 2020 Congress, we’re presenting 27 Bristol Myers Squibb-sponsored abstracts, underscoring our commitment to advancing precision medicine and developing more targeted approaches to treating immune-mediated diseases where treatment options are limited or medical unmet needs still exist. The presented data include clinical, real-world and biomarker studies that focus on furthering precision medicine in rheumatoid arthritis as well as other conditions, including juvenile idiopathic arthritis.

Check out the latest educational resources below:


Web of discovery
Explore immune system interconnectivity.
Destination: The Impact of Precision Medicine in Disease Management for People with Immune-Mediated Diseases
Destination: The impact of precision medicine in disease management for people with immune-mediated diseases
Our Dr. Brian Gavin discusses precision medicine for immune-mediated diseases, including rheumatoid arthritis and systemic lupus erythematosus.
Our Precision-Focused Approach in RA and Beyond
Our precision-focused approach in RA and beyond: A Q&A with Dr. Sean E. Connolly
Our Dr. Sean E. Connolly explains our precision medicine research approach and shares a video on the potential role of biomarkers.
Disease State Infographics
Disease state infographics
Learn about the immune-mediated diseases we’re researching.
Spotlight: Rheumatoid Arthritis
Spotlight: Rheumatoid arthritis 
Learn more about this destructive immune-mediated disease and how it can behave differently in different people.
Spotlight: Juvenile Idiopathic Arthritis
Spotlight: Juvenile idiopathic arthritis
Get the facts on the most common chronic rheumatic disease affecting children and teens.